BiotechTube
VaxCyte

VaxCyte

PCVX
San Carlos, United States· Est.

VaxCyte is pioneering the development of broad-spectrum bacterial vaccines to address significant unmet medical needs in pneumococcal disease, Group A Strep, and Shigella infections. Their cell-free protein synthesis platform enables the production of high-fidelity vaccines with enhanced immunogenicity and broader serotype coverage than conventional approaches. The company's lead candidate VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in clinical development, designed to cover over 95% of invasive pneumococcal disease in adults aged 50 and older. With three Phase 3 trials underway and topline data expected in Q4 2026, VaxCyte is well-positioned to potentially set a new standard of care in pneumococcal vaccination.

vaxcyte.com

PCVX · Stock Price

USD 55.91-14.86 (-21.00%)
Market Cap: $8.1B

Historical price data

AI Company Overview

VaxCyte is pioneering the development of broad-spectrum bacterial vaccines to address significant unmet medical needs in pneumococcal disease, Group A Strep, and Shigella infections. Their cell-free protein synthesis platform enables the production of high-fidelity vaccines with enhanced immunogenicity and broader serotype coverage than conventional approaches. The company's lead candidate VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in clinical development, designed to cover over 95% of invasive pneumococcal disease in adults aged 50 and older. With three Phase 3 trials underway and topline data expected in Q4 2026, VaxCyte is well-positioned to potentially set a new standard of care in pneumococcal vaccination.

VaccinesInfectious DiseasesPneumococcal DiseaseBacterial Infections

Technology Platform

Cell-free protein synthesis platform that enables rapid engineering and manufacturing of high-fidelity, broad-spectrum vaccines with site-specific conjugation and carrier-sparing design to overcome limitations of conventional cell-based vaccine approaches.

Pipeline

8
8 drugs in pipeline3 in Phase 3
DrugIndicationStageWatch
31-valent pneumococcal conjugate vaccine + Seasonal Influenz...Pneumococcal VaccinesPhase 3
31 valent pneumococcal conjugate vaccine + PCV20 + PCV21Pneumococcal VaccinesPhase 3
31-valent pneumococcal conjugate vaccine + PCV20Pneumococcal VaccinesPhase 3
0.5 ml dose of 1.1 mcg VAX-24 + 0.5 ml dose of PCV20 + 0.5 m...Pneumococcal VaccinesPhase 2
24-Valent Pneumococcal Conjugate Vaccine + Pneumococcal 20-v...Pneumococcal VaccinesPhase 2

Opportunities

VaxCyte is well-positioned to capture significant market share in the large and growing pneumococcal vaccine market with its broadest-spectrum vaccine candidates.
The company's cell-free platform technology provides opportunities for expansion into additional bacterial vaccine markets including Group A Strep and Shigella, while potential partnerships with major pharmaceutical companies could accelerate global commercialization.

Risk Factors

Key risks include clinical trial execution challenges, regulatory approval uncertainty, and intense competition from established vaccine manufacturers like Pfizer and Merck.
The company faces significant commercial risks related to market acceptance, pricing pressures, and the need to demonstrate superior clinical outcomes to displace existing standard-of-care vaccines.

Competitive Landscape

VaxCyte competes in the established pneumococcal vaccine market dominated by Pfizer's Prevnar franchise and Merck's Vaxneuvance, but differentiates through its highest-in-class 31-valent coverage and novel cell-free synthesis platform. The company's broader serotype coverage and potential for superior immunogenicity could provide competitive advantages, though success depends on demonstrating clinical superiority over well-established competitors.

More companies in Biologics / Biosimilars →More companies in United States →